Gilead inks $66M+ deal with Tentarix in oncology, inflammatory diseases

Tentarix Biotherapeutics is emerging from its den to ink a multi-pronged deal with Gilead Sciences to work on therapies for oncology and inflammatory diseases worth $66 million upfront, including an equity payment.